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Objectives: The aim of this study was to evaluate the impact of a bundle called FAST HUG in
ventilator-associated pneumonia, weigh the healthcare costs of ventilator-associated pneu-
monia patients in the intensive care unit, and hospital mortality due to ventilator-associated
pneumonia.
Material and methods: The study was performed in a private hospital that has an 8-bed inten-
sive  care unit. It was divided into two phases: before implementing FAST HUG, from August
2011 to August 2012 and after the implementation of FAST HUG, from September 2012 to
December 2013. An individual form for each patient in the study was ﬁlled out by using
information taken electronically from the hospital medical records. The following data was
obtained from each patient: age, gender, reason for hospitalization, use of three or more
antibiotics, length of stay, intubation time, and outcome.
Results: After the implementation of FAST HUG, there was an observable decrease in the
occurrence of ventilator-associated pneumonia (p < 0.01), as well as a reduction in mortality
rates  (p < 0.01). In addition, the intervention resulted in a signiﬁcant reduction in intensive
care unit hospital costs (p < 0.05).
Conclusion: The implementation of FAST HUG reduced the number of ventilator-associatedpneumonia cases. Thus, decreasing costs, reducing mortality rates and length of stay, which
therefore resulted in an improvement to the overall quality of care.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
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E-mail address: denise.roder@ufu.br (D.V.D.d.B. Röder).
ttp://dx.doi.org/10.1016/j.bjid.2016.03.004
413-8670/© 2016 Elsevier Editora Ltda. This is an op
http://creativecommons.org/licenses/by-nc-nd/4.0/).en access article under the CC BY-NC-ND license
i s . 2 0268  b r a z j i n f e c t d 
Introduction
Ventilator-associated pneumonia (VAP) is the second most
common health care-associated infections (HAI) in the United
States and is responsible for 25–42% of all infections that occur
in intensive care units (ICUs). Among those patients requiring
mechanical ventilation, mortality rates are 46% in patients
with VAP.1–3 Patients with VAP have signiﬁcantly increases
the length of hospital stay and thus healthcare costs. This
however could be reduced if steps are taken to improve the
care provided for the ventilated patient. Therefore, the pre-
vention of VAP must be a priority in the care of critically ill
patients.4–6
Health professionals continually strive to improve the care
provided for patients admitted to ICU.3 The results of recent
quality improvement initiatives suggest that many  cases of
VAP could be prevented by paying careful attention when
delivering care, which is the primary role of the FAST HUG
checklist. FAST HUG is a mnemonic aid to ICU healthcare
professionals to prepare for patient rounds, help identify and
prevent medication errors, promote patient safety, and maxi-
mize therapeutic interventions.3,7
In this study, we  evaluate the impact of FAST HUG in the
occurrence of VAP, weigh the healthcare costs of VAP patients
in the ICU, and hospital mortality due to VAP.
Materials  and  methods
Study  design
The study was performed in a private hospital in the city
of Uberlandia, Minas Gerais-Brazil that has an 8-bed ICU.
It was divided into two phases: before implementing FAST
HUG, from August 2011 to August 2012 and after the imple-
mentation of FAST HUG, from September 2012 to December
2013. The research was conducted after the approval of the
Ethics Committee on Human Research of the Federal Univer-
sity of Uberlandia, according to the registry protocol CEP/UFU:
442.151/2013.
An individual form for each patient in the study was ﬁlled
out by using information taken electronically from the hos-
pital medical records. The following data was obtained from
each patient: age, gender, reason for hospitalization, use of
three or more  antibiotics, length of stay, intubation time, and
clinical outcome. Furthermore, the FAST HUG checklist, which
corresponds to 10 items, was followed and printed out daily
by the nursing staff.
The study inclusion criteria were age over 18 years, be
hospitalized at the study hospital, and using a mechanical
ventilator (MV) for over 48 h.
Deﬁnitions
FAST HUG is a checklist that highlights key aspects of gen-
eral care for critically ill patients. The mnemonic aid stresses
the importance of the following clinical practices: feeding,
analgesia, sedation, thromboembolic prophylaxis, head of
bed elevation, stress ulcer prophylaxis, and glycemic control. 1 6;2  0(3):267–271
FAST HUG can be applied to all ICU patients.3 According to
scientiﬁc literature, there are also three important actions to
be taken in order to reduce VAP, which are: oral hygiene with
2% chlorhexidine, monitoring cuff pressure between 20 and
25 cm of water, and subglottic suction every six hours or when-
ever necessary.2,3
VAP: mechanically ventilated patients whose condition has
evolved to the point where a new or progressive pulmonary
inﬁltrate in a chest X-ray. The deﬁnition also requires at least
two clinical signs and/or laboratory abnormalities that sug-
gest an infectious process such as: fever (>38 ◦C); leukocytosis
(>10,000 mm–3) or leukopenia (<4000 mm–3); presence of puru-
lent tracheal secretion after 48 h of ventilation.1,3,8
Statistical  analysis
The Kolmogorov–Smirnov and Shapiro–Wilk tests were used
to test the normality of all the variables. The Mann–Whitney
test was used for the continuous variables with non-
parametric distribution and the Wilcoxon test for analyzing
the intra-group. Kaplan Meier and Cox regression sur-
vival analyses was also used. The chi-square test was
applied to compare categorical variables. Furthermore, a
binary logistic regression analysis was performed among the
groups.
Results
In total 188 patients were included in the survey, with 56
patients in 2011, 79 patients in 2012 and 53 patients in 2013,
of which 37 patients had VAP, 20 of whom were diagnosed
clinically and 17 clinically and microbiologically.
Table 1 shows the statistical comparison of the patients’
clinical characteristics of those with and without VAP. The
variables associated with VAP in univariate analysis were
use three or more  antibiotics prior to infection (p < 0.001);
enteral nutrition while in the ICU (p < 0.01); and tracheostomy
(p < 0.01). VAP associated mortality rate was 64% (p < 0.05) and
lastly, the presence of infection represented an additional hos-
pital cost of R$ 7302.70 per day (p < 0.01). Through multivariate
analysis (Table 2), it was observed that age was an independent
factor for VAP (p < 0.05; OR 26.99).
The demographic and clinical characteristics of the group
of patients with and without the FAST HUG  checklist are
shown in Table 3. In univariate analysis, the number of
antibiotic-therapy days was signiﬁcantly higher for those
who used three or more  antibiotics (p < 0.001). Furthermore,
by using APACHE II, patients undergoing FAST HUG had
more  severe clinical conditions at admission (p < 0.01), which
increased the mortality risk (p < 0.05). However, after the
implementation of FAST HUG, there was a decreased occur-
rence of VAP among these patients (p < 0.01), as well as a
mortality reduction (p < 0.01). Additionally, the intervention
performed in the study resulted in a signiﬁcant reduction in
ICU hospital costs (p < 0.05).
Through logistic regression analysis, signiﬁcantly less days
of antibiotic use (p < 0.0001) and a lower mortality rate (p < 0.05)
could be seen as a result of FAST HUG.
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Table 1 – Clinical characteristics of patients admitted to a Brazilian hospital on mechanical ventilation from July 2011 to
December 2013.
Variables VAP (n = 37) No VAP (n = 151) p Value OR
Gender (M/F) 26(70.3%) 11 (29.7%) 84(55.6%) 67 (44.4%) 0.10 0.53 (0.24–1.15)
Age, y (≥65, <65) 23(62.2%) 14 (37.8%) 68(45.1%) 83 (54.9%) 0.06 2.0 (0.95–4.19)
Antibioticsa 33 (89.2%) 46 (30.9%) <0.01c 18.83 (6.30–56.23)
Enteral nutrition 36 (97.3%) 77 (51%) <0.01c 34.59 (4.62–258.84)
Tracheostomy 30 (81.1%) 31 (20.5%) <0.01c 16.59 (6.66–41.32)
APACHE II 18.51 ± 10.83 16.0 ± 9.9 0.2 –
APACHE IIb 36.30 ± 27.18 28.23 ± 22.49 0.06 –
Death 24 (64%) 68 (59%) <0.05c –
Daily cost (R$) 9550.81 ± 6172.21 2248.11 ± 607.20 <0.01c –
APACHE, Acute Physiological and Chronic Health Evaluation; F, female; M, male; OR odds ratio; VAP, ventilator-associated pneumonia; R$,
Brazilian currency.
a Means ≥3 antibiotics class.
b Mortality risk;
c p ≤ 0.05.
Table 2 – Logistic regression analysis of the clinical characteristics of patients on mechanical ventilation admitted to a
Brazilian hospital from July 2011 to December 2013.
Variables VAP (n = 37) No VAP (n = 151) p Value OR
Gender (M/F) 26(70.3%) 11 (29.7%) 84(55.6%) 67 (44.4%) 0.62 0.58 (0.68–5.09)
Age, y (≥65, <65) 23(62.2%) 14 (37.8%) 68(45.1%) 83 (54.9%) 0.05c 26.99 (1.16–627.33)
Antibioticsa 33 (89.2%) 46 (30.9%) 0.16 10.21 (0.54–190.73)
Tracheostomy 30 (81.1%) 31 (20.5%) 0.16 33.90 (1.91–601.5)
APACHE II 18.51 ± 10.83 16.0 ± 9.9 0.38 –
APACHE IIb 36.30 ± 27.18 28.23 ± 22.49 0.93 –
APACHE, Acute Physiological and Chronic Health Evaluation; F, female; M, male; OR odds ratio; VAP, ventilator-associated pneumonia.
t
u
a
aa Means ≥3 antibiotics class.
b Mortality risk.
c p ≤ 0.05.
The survival analysis showed that longer length of stay in
he ICU was associated lower survival (Fig. 1), and that patients
ndergoing FAST HUG survived longer. Cox regression was
djusted to the risk factors identiﬁed in the logistic regression
nalysis; antibiotics, enteral nutrition and tracheotomy cases
Table 3 – Analysis of demographic and clinical characteristics o
Brazilian hospital from July 2011 to December 2013.
Variables No FAST HUG (n = 115) FAS
Gender (M/F) 57/43 35/
Age, y (≥65, <65) 58 (50.4%) 33 
Hospitalization (days) 16 (8.5–35.5) 19 
Antibiotics (days) 17 (9–140) 8 (5
Antibioticsa 71 (62%) 25 
Surgical 6 (5%) 3 (4
Clinical 101 (88%) 66 
Trauma 9 (8%) 6 (8
MV time 14 (6–140) 15 
APACHE II 14.75 ± 9.8 20.
APACHE IIb 26 ± 22 35 ±
VAP 30 (26) 7 (9
Death 70 (60) 22 
Daily cost (R$) 6700.20 ± 26,154.29 633
APACHE, Acute Physiological and Chronic Health Evaluation; F, female; M
associated pneumonia; R$, the Brazilian currency.
a Means ≥3 antibiotics class.
b Mortality risk.
c p ≤ 0.05.showed events at 38% and censoring 59%, with similarity of
the two groups (p > 0.05).
However, there was no survival difference between the two
groups in the ﬁrst 20 days of admission. However, considering
the ﬁrst 80 days of hospitalization, 50% of the FAST HUG group
f patients with and without FAST HUG admitted to a
T HUG (n = 73) p Value OR
65 0.86 –
(45%) 0.80 –
(9–47) 0.32 0.99 (0.98–1.0)
–57) <0.001c –
(34%) <0.001c –
%) 0.72 0.77 (0.18–3.21)
(90%) 0.58 1.37 (0.5–3.4)
%) 0.92 1.05 (0.35–3.09)
(5–139) 0.16 0.99 (0.98–1.0)
22 ± 9.87 <0.01c –
 26 <0.05c –
,6) <0.01c 0.30 (0.12 –0.32)
(30) <0.01c 0.27 (0.14–0.51)
9.34 ± 24,529.83 <0.05c –
, male; MV, mechanical ventilation; OR odds ratio; VAP, ventilator-
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Fig. 1 – Survival rate for patients with and without FAST
HUG.
survived compared to 20% for those without the intervention.
Additionally, as the longer the length of stay, the lower the
survival rate for patients without the intervention.
Discussion
VAP is common in patients that are connected to mechanical
ventilators over long periods. Therefore, the criteria used for
diagnosing VAP is essential.9 Although there are various def-
initions of VAP, in this study the criteria fever, leucocytosis,
chest X-ray with presence with new and progressive pul-
monary inﬁltrates, and microbiological culture are utilized, as
these are recommended by the American Thoracic Society3,8;
these criteria also present low cost and are commonly used
by ICUs for the diagnosis of VAP. On the other hand, these
criteria have limitations: there are patients who despite hav-
ing present VAP symptoms, do not fulﬁll the more  rigorous
criteria and would therefore be missed as having VAP.9 VAP is
a health care related infection and is the second leading cause
of nosocomial infections linked to morbidity and mortality.10
Therefore, the implementation of care guidelines protocols
has become necessary for the adequate treatment and care
of critically ill patients in ICUs.3,5 An excellent alternative is
the creation of checklists. They are simple and easily imple-
mented by multidisciplinary teams working in a hospital.7,11
In order to reach the goals of this study, the authors
assumed that a checklist is an indispensable tool for safety
and care of critically ill patients. It is suggested that health-
care workers who make bedside rounds adopt a memorization
technique of one sentence. This can be associated to a letter
to represent the problems that must be evaluated and cor-
rected daily in critically ill patients. Through the expression
or acronym FAST HUG, clinical aspects of great importance
are highlighted such as nutrition, analgesia, headboard height,
and others that characterize prophylactic measures for VAP.7
In relation to the research, various risk factors (the
use of more  than three antibiotics, enteral nutrition, and 1 6;2  0(3):267–271
tracheotomy) were signiﬁcantly associated with VAP. The use
of antibiotics has been shown in scientiﬁc literature to make
up to 50% of all prescriptions in the ICU for patients with
VAP.12,13 Regarding enteral nutrition, it is well known that
a catheter is present in almost all patients with a MV and
increasing the PH increases the risk of VAP, a predisposition
to gastric colonization, which thus increase the risk of reﬂux
and aspirations pneumonitis.14 Research conducted in 2003
showed that enteral nutrition was an independent risk fac-
tor for VAP (p < 0.001), as well as tracheostomy (p < 0.001).15
Another study showed, through logistic regression analysis,
that tracheostomy (p < 0.001) was an independent risk factor
that can lead to the development of VAP.16
In this study, a statistically signiﬁcant additional medical
cost was seen in patients with VAP. This has been proven
by other studies in the United States, which showed that
hospital expenses are signiﬁcantly higher for patients with
VAP ($ 104,983), compared to those without VAP ($ 63,689)
[p = 0.001].17 In 2012, a project was developed with the aim
of reducing VAP rates, which resulted in a decline from 9.47
to 1.9 cases per 1000 ventilator days and thus, producing an
estimated savings of approximately $1.5 million.18
In addition, the search for improving the quality of care
linked to critically ill patients, thus reducing hospital mor-
tality, and the use of hospital quality indicators, which can
lead to better care and lower costs, have been targets of major
global agencies aimed at preventing diseases and iatrogene-
sis. Therefore, it is essential to use what has come to be known
as packaged measures.14 In applying FAST HUG  to critically ill
patients daily, resulted in: a decrease in antibiotics use, lower
mortality rates, lower hospital costs, and most importantly,
it signiﬁcantly reduced the number of VAP cases. Not to be
forgotten that patients diagnosed with a severe illness at hos-
pital admittance have higher mortality risk. Patients who  were
part of the FAST HUG program were more  likely to survive than
those without the intervention. A study published in 2008 in an
ICU of an American University Medical Center showed a sig-
niﬁcant reduction of VAP cases after implementing FAST HUG.
The rate before FAST HUG implementation was 16.6 cases
of VAP per 1000 days of mechanical ventilation, dropped to
1.3 cases after the implementation.19 A multicenter study of
ICUs in the United States and Canada between 2002 and 2004
showed signiﬁcant reduction in VAP, and other more  recent
studies have shown that implementing FAST HUG caused a
41% reduction rate in VAP.20,21
Conclusion
The implementation of FAST HUG reduced the number of
VAP cases, the mortality rate and hospital costs, as well
as improved the quality of care. FAST HUG is a package of
relatively simple actions that does not overload healthcare
professionals, and does not lead to an increase in hospi-
tal costs. Its implementation requires nothing more  than an
administrative decision and personnel preparation and train-
ing to bring beneﬁts, particularly to patients. Due to the
relative simplicity linked to the program, it can be extended
to different public and private institutions without interfering
with other plans of action.
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